Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology
  • API Reference

© 2026 Annolyse.

←Back to insights

Insights

NZX leverage comparison

Net debt and net debt / EBITDA across the Annolyse coverage set, ranked by the latest reported leverage position.

Last updated 2 July 2026

Leverage trend

Net debt / EBITDA across covered companies; net-cash and ratios above 50x are omitted from the chart.

↗
Loading chart...
  • FY22 AOF: Outside range high net debt / ebitda. 0.7x; 3-period range -2.17x to -0.09x. Net debt / EBITDA: 0.70x, above normal range; 3-period mean -1.26x, range -2.17x--0.09x.
  • FY21 AIA: Outside range low net debt / ebitda. 1.8x; 4-period range 2.32x to 8.3x. Net debt / EBITDA: 1.80x, below normal range; 4-period mean 4.81x, range 2.32x-8.30x.
  • HY22 AIA: Unprecedented high net debt / ebitda. 23.5x; 4-period range 4.96x to 15.81x. Net debt / EBITDA: 23.50x, unprecedented high; 4-period mean 8.49x, range 4.96x-15.81x.
  • FY24 AIA: Unprecedented high net debt / ebitda. 8.3x; 4-period range 1.8x to 4.31x. Net debt / EBITDA: 8.30x, unprecedented high; 4-period mean 3.18x, range 1.80x-4.31x.
  • HY25 AIA: Outside range low net debt / ebitda. 4.96x; 4-period range 6.2x to 23.5x. Net debt / EBITDA: 4.96x, below normal range; 4-period mean 13.13x, range 6.20x-23.50x.
  • FY21 CHI: Unprecedented low net debt / ebitda. 2.52x; 4-period range 3.14x to 4.5x. Net debt / EBITDA: 2.52x, unprecedented low; 4-period mean 3.70x, range 3.14x-4.50x.
  • HY22 CHI: Outside range high net debt / ebitda. 10.94x; 3-period range 6.2x to 6.8x. Net debt / EBITDA: 10.94x, above normal range; 3-period mean 6.60x, range 6.20x-6.80x.
  • FY22 CHI: Unprecedented high net debt / ebitda. 4.5x; 4-period range 2.52x to 3.6x. Net debt / EBITDA: 4.50x, unprecedented high; 4-period mean 3.20x, range 2.52x-3.60x.
  • HY25 CHI: Outside range low net debt / ebitda. 6.2x; 3-period range 6.8x to 10.94x. Net debt / EBITDA: 6.20x, below normal range; 3-period mean 8.18x, range 6.80x-10.94x.
  • HY23 CNU: Outside range low net debt / ebitda. 6.55x; 3-period range 7.46x to 8.89x. Net debt / EBITDA: 6.55x, below normal range; 3-period mean 8.15x, range 7.46x-8.89x.
  • HY26 CNU: Outside range high net debt / ebitda. 8.89x; 3-period range 6.55x to 8.1x. Net debt / EBITDA: 8.89x, above normal range; 3-period mean 7.37x, range 6.55x-8.10x.
  • FY24 CCC: Outside range high net debt / ebitda. 4.65x; 3-period range 1.33x to 3.6x. Net debt / EBITDA: 4.65x, above normal range; 3-period mean 2.57x, range 1.33x-3.60x.
  • FY26 CCC: Outside range low net debt / ebitda. 1.33x; 3-period range 2.77x to 4.65x. Net debt / EBITDA: 1.33x, below normal range; 3-period mean 3.67x, range 2.77x-4.65x.
  • FY21 FBU: Outside range low net debt / ebitda. 0.17x; 3-period range 1.2x to 2.12x. Net debt / EBITDA: 0.17x, below normal range; 3-period mean 1.61x, range 1.20x-2.12x.
  • FY24 FBU: Outside range high net debt / ebitda. 2.12x; 3-period range 0.17x to 1.51x. Net debt / EBITDA: 2.12x, above normal range; 3-period mean 0.96x, range 0.17x-1.51x.
  • HY23 GNE: Outside range low net debt / ebitda. 4.4x; 3-period range 4.6x to 6.6x. Net debt / EBITDA: 4.40x, below normal range; 3-period mean 5.88x, range 4.60x-6.60x.
  • HY25 GNE: Outside range high net debt / ebitda. 6.6x; 3-period range 4.4x to 6.43x. Net debt / EBITDA: 6.60x, above normal range; 3-period mean 5.14x, range 4.40x-6.43x.
  • FY22 MFT: Outside range high net debt / ebitda. 0x; 3-period range -0.14x to -0.02x. Net debt / EBITDA: 0.00x, above normal range; 3-period mean -0.06x, range -0.14x--0.02x.
  • HY22 MCY: Unprecedented high net debt / ebitda. 6.68x; 4-period range 3.91x to 5.03x. Net debt / EBITDA: 6.68x, unprecedented high; 4-period mean 4.42x, range 3.91x-5.03x.
  • FY22 MCY: Outside range high net debt / ebitda. 3.25x; 3-period range 2.16x to 2.79x. Net debt / EBITDA: 3.25x, above normal range; 3-period mean 2.37x, range 2.16x-2.79x.
  • HY23 MCY: Outside range low net debt / ebitda. 3.91x; 4-period range 4.23x to 6.68x. Net debt / EBITDA: 3.91x, below normal range; 4-period mean 5.11x, range 4.23x-6.68x.
  • FY24 MCY: Outside range low net debt / ebitda. 2.16x; 3-period range 2.17x to 3.25x. Net debt / EBITDA: 2.16x, below normal range; 3-period mean 2.74x, range 2.17x-3.25x.
  • HY23 MEL: Outside range low net debt / ebitda. 2.2x; 3-period range 2.64x to 6.01x. Net debt / EBITDA: 2.20x, below normal range; 3-period mean 3.99x, range 2.64x-6.01x.
  • HY25 MEL: Outside range high net debt / ebitda. 6.01x; 3-period range 2.2x to 3.33x. Net debt / EBITDA: 6.01x, above normal range; 3-period mean 2.72x, range 2.20x-3.33x.
  • HY25 MPG: Unprecedented high net debt / ebitda. 5.99x; 4-period range 2.9x to 3.9x. Net debt / EBITDA: 5.99x, unprecedented high; 4-period mean 3.45x, range 2.90x-3.90x.
  • FY25 MPG: Unprecedented high net debt / ebitda. 10.8x; 4-period range 1.5x to 4.3x. Net debt / EBITDA: 10.80x, unprecedented high; 4-period mean 2.78x, range 1.50x-4.30x.
  • HY26 MPG: Outside range low net debt / ebitda. 2.9x; 4-period range 3.2x to 5.99x. Net debt / EBITDA: 2.90x, below normal range; 4-period mean 4.22x, range 3.20x-5.99x.
  • FY26 MPG: Outside range low net debt / ebitda. 1.5x; 4-period range 2.12x to 10.8x. Net debt / EBITDA: 1.50x, below normal range; 4-period mean 5.11x, range 2.12x-10.80x.
  • HY23 MFB: Outside range low net debt / ebitda. 0.51x; 3-period range 0.77x to 1.91x. Net debt / EBITDA: 0.51x, below normal range; 3-period mean 1.29x, range 0.77x-1.91x.
  • FY23 MFB: Outside range high net debt / ebitda. 0.84x; 3-period range -0.1x to 0.43x. Net debt / EBITDA: 0.84x, above normal range; 3-period mean 0.15x, range -0.10x-0.43x.
  • HY24 MFB: Outside range high net debt / ebitda. 1.91x; 3-period range 0.51x to 1.2x. Net debt / EBITDA: 1.91x, above normal range; 3-period mean 0.83x, range 0.51x-1.20x.
  • HY25 OCA: Outside range high net debt / ebitda. 16.27x; 3-period range 12.9x to 16.2x. Net debt / EBITDA: 16.27x, above normal range; 3-period mean 14.60x, range 12.90x-16.20x.
  • FY22 PHL: Outside range low net debt / ebitda. 3.3x; 3-period range 5.82x to 8x. Net debt / EBITDA: 3.30x, below normal range; 3-period mean 7.15x, range 5.82x-8.00x.
  • FY23 PHL: Outside range high net debt / ebitda. 8x; 3-period range 3.3x to 7.64x. Net debt / EBITDA: 8.00x, above normal range; 3-period mean 5.59x, range 3.30x-7.64x.
  • FY23 RAD: Outside range high net debt / ebitda. 7x; 3-period range 2.51x to 3.5x. Net debt / EBITDA: 7.00x, above normal range; 3-period mean 2.97x, range 2.51x-3.50x.
  • FY26 RAD: Outside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x.
  • FY22 SVR: Unprecedented high net debt / ebitda. 4.03x; 5-period range 0.79x to 2.27x. Net debt / EBITDA: 4.03x, unprecedented high; 5-period mean 1.41x, range 0.79x-2.27x.
  • FY26 SVR: Outside range low net debt / ebitda. 0.79x; 5-period range 1x to 4.03x. Net debt / EBITDA: 0.79x, below normal range; 5-period mean 2.06x, range 1.00x-4.03x.
  • HY22 SCL: Outside range low net debt / ebitda. 0.06x; 3-period range 0.77x to 1.33x. Net debt / EBITDA: 0.06x, below normal range; 3-period mean 1.03x, range 0.77x-1.33x.
  • HY24 SCL: Outside range high net debt / ebitda. 1.33x; 3-period range 0.06x to 0.98x. Net debt / EBITDA: 1.33x, above normal range; 3-period mean 0.60x, range 0.06x-0.98x.
  • HY24 SCT: Outside range high net debt / ebitda. 1.2x; 4-period range -0.88x to 1.1x. Net debt / EBITDA: 1.20x, above normal range; 4-period mean 0.57x, range -0.88x-1.10x.
  • FY24 SCT: Outside range high net debt / ebitda. 0.66x; 3-period range -0.06x to 0.4x. Net debt / EBITDA: 0.66x, above normal range; 3-period mean 0.21x, range -0.06x-0.40x.
  • FY23 SEK: Outside range high net debt / ebitda. 6.63x; 3-period range 1.05x to 3.2x. Net debt / EBITDA: 6.63x, above normal range; 3-period mean 2.02x, range 1.05x-3.20x.
  • FY25 SEK: Outside range low net debt / ebitda. 1.05x; 3-period range 1.8x to 6.63x. Net debt / EBITDA: 1.05x, below normal range; 3-period mean 3.88x, range 1.80x-6.63x.
  • FY23 SPK: Outside range low net debt / ebitda. 0.55x; 3-period range 1.18x to 1.38x. Net debt / EBITDA: 0.55x, below normal range; 3-period mean 1.30x, range 1.18x-1.38x.
  • FY25 SPK: Outside range high net debt / ebitda. 1.38x; 3-period range 0.55x to 1.34x. Net debt / EBITDA: 1.38x, above normal range; 3-period mean 1.02x, range 0.55x-1.34x.
← Swipe to view more
NZX leverage comparison table
CompanyTickerPeriodNet debt / EBITDANet debtPrior comparableDirection
Steel & Tube HoldingsSTUHY2635.86x$43m—n/a
Precinct PropertiesPCTHY2620.39x$1.5b—n/a
Oceania HealthcareOCAHY2614.67x$608.9m16.2xImproved
Property for IndustryPFIHY2613.87x$765.4m—n/a
VectorVCTHY269.48x$2.1b5.05xDeteriorated
InfratilIFTFY269.09x$6.3b8.82xDeteriorated
ChorusCNUHY268.89xOutside range highOutside range high net debt / ebitda. 8.89x; 3-period range 6.55x to 8.1x. Net debt / EBITDA: 8.89x, above normal range; 3-period mean 7.37x, range 6.55x-8.10x.$3.2b8.1xDeteriorated
Meridian EnergyMELHY266.8x$3.4b6.01xDeteriorated
SkyCity Entertainment GroupSKCHY266.8x$490.4m5.21xDeteriorated
ComvitaCVTHY266.33x$48.7m14.03xImproved
Auckland International AirportAIAHY266.17x$2.3b5xDeteriorated
Promisia HealthcarePHLFY265.82x$38.5m—n/a
Napier Port HoldingsNPHHY264.72x$129.5m1.61xDeteriorated
Delegat GroupDGLHY264.68x$307m5.6xImproved
Genesis EnergyGNEHY264.6x$1.4b6.6xImproved
Vulcan SteelVSLHY254.24x$241.5m—n/a
Mercury NZMCYHY264.23x$2.3b5.03xImproved
Tourism HoldingsTHLHY263.92x$492.6m4.21xImproved
Port of TaurangaPOTHY263.85x$471.2m—n/a
PGG WrightsonPGWHY263.73x$170.7m1.52xDeteriorated
Channel Infrastructure NZCHIFY253.55x$331.8m3.14xDeteriorated
T&G Global Limited and subsidiary companiesTGGFY253.14x$147.2m13.25xImproved
Spark New ZealandSPKHY263.12x$1.4b1.38xDeteriorated
Radius Residential CareRADFY262.51xOutside range lowOutside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x.$68.7m4.27xImproved
The Colonial Motor CompanyCMOHY262.38x$36.4m—n/a
Goodman Property TrustGNZHY262.01x$167m9.39xImproved
South Port New ZealandSPNHY261.91x$29.1m0.97xDeteriorated
SanfordSANHY261.6x$102.1m0.92xDeteriorated
KMD BrandsKMDHY261.48x$94m1.4xDeteriorated
Metro Performance GlassMPGFY261.48xOutside range lowOutside range low net debt / ebitda. 1.5x; 4-period range 2.12x to 10.8x. Net debt / EBITDA: 1.50x, below normal range; 4-period mean 5.11x, range 2.12x-10.80x.$27m10.8xImproved
Freightways GroupFRWHY261.47x$211m1.82xImproved
Cooks Coffee CompanyCCCFY261.34xOutside range lowOutside range low net debt / ebitda. 1.33x; 3-period range 2.77x to 4.65x. Net debt / EBITDA: 1.33x, below normal range; 3-period mean 3.67x, range 2.77x-4.65x.$1.7m4.65xImproved
SeekaSEKFY251.05xOutside range lowOutside range low net debt / ebitda. 1.05x; 3-period range 1.8x to 6.63x. Net debt / EBITDA: 1.05x, below normal range; 3-period mean 3.88x, range 1.80x-6.63x.$100.3m1.8xImproved
Scott TechnologySCTHY261x$13.1m1.1xImproved
AFC Group HoldingsAFCFY250.94x$0.06m—n/a
SavorSVRFY260.79xOutside range lowOutside range low net debt / ebitda. 0.79x; 5-period range 1x to 4.03x. Net debt / EBITDA: 0.79x, below normal range; 5-period mean 2.06x, range 1.00x-4.03x.$6.3m0.99xImproved
AoFrioAOFFY220.67xOutside range highOutside range high net debt / ebitda. 0.7x; 3-period range -2.17x to -0.09x. Net debt / EBITDA: 0.70x, above normal range; 3-period mean -1.26x, range -2.17x--0.09x.$1.1m—Moved to net debt
Scales CorporationSCLFY250.49x$84.1m0.77xImproved
Skellerup HoldingsSKLHY260.35x$17.5m0.13xDeteriorated
Henderson Far East IncomeHFLHY260.25x$24.8m—n/a
NZMENZMFY250.25x$15.5m0.45xImproved
My Food Bag GroupMFBFY260.11x$1.9m0.43xImproved
ArborGen HoldingsARBFY26—$25.1m—n/a
Argosy PropertyARGFY26—$852.1m14.36xn/a
Australian Foundation Investment CompanyAFIHY26—-$131.6m—Reduced net cash
Blackwell Global HoldingsRTOHY26—-$0.22m—Reduced net cash
BLIS TechnologiesBLTFY26—-$4m—n/a
Briscoe GroupBGPFY26—-$145.6m—Increased net cash
Enprise GroupENSFY25—-$0.5m—Reduced net cash
Fisher & Paykel HealthcareFPHFY26—-$401.3m—Increased net cash
Goodman Property TrustGMTFY26—$693.5m—n/a
Green Cross HealthGXHFY26—-$8.6m0.11xIncreased net cash
Livestock Improvement CorporationLICHY26—-$34.7m—Increased net cash
Me TodayMEEHY26—$0.02m—n/a
Michael Hill InternationalMHJHY26—-$20.7m—Moved to net cash
Millennium & Copthorne Hotels New ZealandMCKFY25—-$0.36m—Reduced net cash
MOVE Logistics GroupMOVHY26—$12.8m1.05xn/a
New Zealand King Salmon InvestmentsNZKHY26—-$38.2m—Reduced net cash
New Zealand Rural Land CompanyNZLHY22—$86.1m—n/a
Pacific EdgePEBHY26—-$14.8m—Reduced net cash
RakonRAKHY26—-$0.85m—Reduced net cash
Rua BioscienceRUAHY26—-$0.4m—Increased net cash
Summerset Group HoldingsSUMFY25—$2b13.62xn/a
Synlait MilkSMLHY26—$472.1m6.21xn/a
Templeton Emerging Markets Investment Trust PlcTEMHY24—-$30.4m—Increased net cash
The a2 Milk CompanyATMHY26—-$896.9m—n/a
The Warehouse GroupWHSFY25—-$19m0.86xMoved to net cash
Third Age Health ServicesTAHFY26—-$1.8m—Increased net cash
Turners Automotive GroupTRAFY26—$566.1m6.96xn/a
Vista Group InternationalVGLFY25—-$0.7m—Reduced net cash
Winton LandWINHY26—$104.9m—n/a

Source: latest published result per company in the current Annolyse coverage set.

NZX leverage comparison table

Copy, export, or share this public Annolyse data reference.

Leverage splits into three buckets. PGW and FBU are the clearest balance-sheet watches, though PGW's first-half leverage is seasonally elevated. SPK and KMD remain levered but still readable on a conventional net-debt-to-earnings basis, while ATM and BGP are net-cash names where the more useful question is whether the cash buffer increased or reduced.

Methodology

Net debt and net debt / EBITDA use standard Annolyse calculations from available filing data. Ratios are suppressed when EBITDA is negative because leverage is not meaningful in that state, and net-cash companies use net-cash direction labels instead of being forced into the same 'improved/deteriorated' language as levered businesses.

Related insights

NZX cash conversion comparison

Operating cash flow versus EBITDA across the Annolyse coverage set, using each company's most recent published result.

NZX dividend coverage comparison

Payout ratios against NPAT and free cash flow for the latest published result from each covered company.

NZX earnings quality comparison

PBT versus NPAT divergence across covered NZX companies, highlighting tax, fair-value, and non-operating distortions.

NZX revenue growth comparison

Revenue growth rates across covered NZX companies, ranked by each company's latest reported period.

NZX ROE comparison

Return on equity across covered NZX companies, with prior-period movement and leverage context.

NZX working capital comparison

Debtor days and inventory days across covered NZX companies, showing where cash is tied up in receivables or stock.

Get updates to NZX leverage comparison

Get the next relevant NZX result briefings and refreshed comparison views by email.